Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q3 2013 · 10-Q
Revenue$38.91K$38.91K+194.3% vs Q3 2012 Net Income-$2.65M-$2.65MN/M vs Q3 2012 EPS Diluted$0.00$0.00— vs Q3 2012 Gross Profit$33,101+269.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$251,568N/M Margins · derivedGross margin85.1%+17.3 pt vs Q3 2012
Operating margin-1399.2%+452.4 pt vs Q3 2012
Net margin-6803.1%−4512.9 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 19, 2013 · 50 d after period end